Could adding capecitabine boost chemo success in Triple-Negative breast cancer?
NCT ID NCT04335669
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether adding the drug capecitabine to standard chemotherapy improves outcomes for people with early triple-negative breast cancer. The study involves 325 participants and aims to see if the combination leads to a higher rate of complete tumor disappearance before surgery. Pembrolizumab is also allowed in both treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine (added to standard chemotherapy drugs epirubicin, cyclophosphamide, paclitaxel, carboplatin, and pembrolizumab)
What this could lead to
If successful, this could lead to a more effective chemotherapy regimen for early triple-negative breast cancer, potentially increasing the chance of a complete response before surgery.
What could go wrong
This is a phase 3 trial, but results are not yet available. Adding capecitabine may increase side effects without improving outcomes, and the study only includes specific patient types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aalborg Universitetshospita
Aalborg, 9000, Denmark
-
Academical Hospital, Department of Oncology
Uppsala, 753 09, Sweden
-
Capio S:t Göran Hospital, Department of Oncology
Stockholm, 112 19, Sweden
-
Centralsjukhuset i Kristianstad
Kristianstad, Skåne County, 291 85, Sweden
-
Gävle hospital, Department of Oncology
Gävle, 803 24, Sweden
-
Halmstad Hospital, Department of Surgery
Halmstad, 302 33, Sweden
-
Karlstad Hospital
Karlstad, 652 30, Sweden
-
Nordsjællands Hospital
Hillerød, 3400, Denmark
-
Norrland University Hospital, Department of Oncology
Umeå, 907 37, Sweden
-
Regionsjælland Næstved Sygehus
Næstved, 4700, Denmark
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Ryhov Hospital
Jönköping, 551 85, Sweden
-
Sahlgrenska University Hospital, Department of Oncology
Gothenburg, 413 46, Sweden
-
Skåne University Hospital, Department of Oncology
Malmö, 20501, Sweden
-
Sundsvall hospital
Sundsvall, 851 86, Sweden
-
Sydvestjysk Sygehus
Esbjerg, 6700, Denmark
-
Södersjukhuset, Department of Oncology
Stockholm, 118 61, Sweden
-
Södra Älvsborgs Hospital
Borås, 501 82, Sweden
-
Sønderborg sygehus
Sønderborg, 6300, Denmark
-
Vejle Hospital
Vejle, Region Syd, 7100, Denmark
-
Vejle syghus
Vejle, 7100, Denmark
-
Västmanlands Hopsital Västerås
Västerås, 721 89, Sweden
-
Växjö Hospital, Department of Oncology
Vaxjo, 352 34, Sweden
-
Örebro University Hospital, Department of Oncology
Örebro, 701 85, Sweden